Ashion Analytics announces innovative cancer treatment partnership with Elevation Oncology

(The Translational Genomics Research Institute) Ashion Analytics today announced a partnership with Elevation Oncology, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra ® test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology. NRG1 gene fusions are a rare genomic alteration implicated as a driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news